A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared with OROS-MPH (CONCERTA®) with a Placebo Reference Arm, in Adolescents Aged 13-17 Years with Attention-deficit/Hyperactivity Disorder (ADHD)

ID Number 13-0029

Principal Investigator(s)
Jeffrey Newcorn

Department(s) or Division(s)


This trial is examining the use of Concerta or Vyvanse in adolescents ages 13-17 who have ADHD.  The purpose of this study is to examine the response to two commonly prescribed stimulant medications that are FDA approved for treatment of ADHD in children and adolescents. The study will include weekly visits with study physicians, evaluations for ADHD and other disorders, and medication for the treatment of ADHD. 

Contact Information
Beth Krone
(212) 241-8012

Recruiting Patients: Yes